摘要
Metabolic reprogramming,a newly recognized trait of tumor biology,is an intensively studied prospect for oncology medicines.For numerous tumors and cancer cell subpopulations,oxidative phosphorylation(OXPHOS)is essential for their biosynthetic and bioenergetic functions.Cancer cells with mutations in isocitrate dehydrogenase 1(IDH1)exhibit differentiation arrest,epigenetic and transcriptional reprogramming,and sensitivity to mitochondrial OXPHOS inhibitors.In this study,we report that berberine,which is widely used in China to treat intestinal infections,acted solely at the mitochondrial electron transport chain(ETC)complex I,and that its association with IDH1 mutant inhibitor(IDH1^(m)i)AG-120 decreased mitochondrial activity and enhanced antileukemic effect in vitro and in vivo.Our study gives a scientific rationale for the therapy of IDH1 mutant acute myeloid leukemia(AML)patients using combinatory mitochondrial targeted medicines,particularly those who are resistant to or relapsing from IDH1m i.
基金
supported by Sichuan Science and Technology Program(No.2022YFS0622)
the Science and Technology Development Fund,Macao SAR(Nos.0036/2020/A1 and 0013/2019/A1).
